Launch of Uritos Tablets for Overactive Bladder in Thailand

Oct 04, 2016 14:35 JST

Source: Eisai

TOKYO, Oct 04, 2016 - (JCN Newswire) - Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand.

Uritos was discovered and developed by KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings who subsequently granted Eisai the exclusive rights to develop and market the agent in China, India, Sri Lanka and ASEAN countries in 2009. This marks the first launch of Uritos in a region where Eisai holds marketing rights to the agent.

Overactive bladder (OAB) is a urological condition marked by a frequent, sudden urge to urinate. It is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. OAB may cause serious issues for patients' quality of life, such as becoming hesitant to go out due to the anxiety of suddenly needing to go to the toilet, or lack of sleep from constantly waking up to use the bathroom at night.

While it is known that OAB becomes more common with age, studies suggest that people with diseases of the brain or spinal cord such as stroke or Parkinson's disease as well as enlargement of the prostate are at high risk of OAB. According to the clinical guidelines for overactive bladder in Japan, the prevalence of OAB in the country ranges from 5 to 20%. Although the prevalence of OAB in Asia is unknown, it was reported that 29.9% of men and 34.7% of women aged over 18 experienced some symptoms of OAB, many of whom did not receive appropriate treatment due to lack of disease awareness.(1)

Uritos is an anticholinergic agent commonly prescribed to treat OAB. It exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with OAB. The most common side effects are thirst and constipation.

Through this launch, Eisai and Kyorin Pharmacetucial strive to improve QOL and further contribute to increasing the benefits for patients with OAB in Thailand.

(1) About Uritos Tablets (generic name: imidafenacin)

Administered orally twice-daily, Uritos is an anticholinergic agent commonly prescribed to treat OAB. It exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with OAB. The most common side effects are thirst and constipation.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Corporate Communcation, 
President's Office KYORIN Holdings, Inc. 
+81-(0)3-3525-4707

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)

April 18 2024 09:53 JST

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan

April 17 2024 15:17 JST

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

April 03 2024 15:24 JST

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

April 01 2024 08:39 JST

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

March 29 2024 14:51 JST

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

March 29 2024 14:19 JST

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

March 29 2024 13:32 JST

Lifenet and Eisai Co-Develop Dementia Insurance "be"

March 21 2024 16:36 JST

Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace

March 21 2024 15:10 JST

Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients

March 06 2024 16:47 JST

More Press release >>

Latest Press Release

JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST

Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST

MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST

GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST

Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST

Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST

UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST

Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST

MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST

Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST

NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST

Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST

Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST

NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST

Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST

TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST

First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST

Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST

Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST

Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST

More Latest Release >>